Icon Public Limited Company (ICLR)

$288.23

-3.59

(-1.23%)▲

Market is closed - opens 7 PM, 22 Apr 2024

Insights on Icon Public Limited Company

  • Increasing Revenue

    Revenue is up for the last 15 quarters, 620.22M → 2.06B (in $), with an average increase of 6.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, 115.59M → 216.41M (in $), with an average increase of 26.9% per quarter

Performance

  • $287.03
    $295.06
    $288.23
    downward going graph

    0.42%

    Downside

    Day's Volatility :2.72%

    Upside

    2.31%

    downward going graph
  • $181.92
    $344.77
    $288.23
    downward going graph

    36.88%

    Downside

    52 Weeks Volatility :47.23%

    Upside

    16.4%

    downward going graph

Returns

PeriodIcon Public Limited CompanySector (Health Care)Index (Russel 2000)
3 Months
8.67%
-0.4%
0.0%
6 Months
27.13%
8.5%
0.0%
1 Year
39.77%
4.2%
-1.2%
3 Years
39.67%
13.9%
-19.2%

Highlights

Market Capitalization
24.1B
Book Value
$112.02
Earnings Per Share (EPS)
7.41
PE Ratio
39.38
PEG Ratio
1.17
Wall Street Target Price
351.31
Profit Margin
7.54%
Operating Margin TTM
13.62%
Return On Assets TTM
3.83%
Return On Equity TTM
6.9%
Revenue TTM
8.1B
Revenue Per Share TTM
98.9
Quarterly Revenue Growth YOY
5.3%
Gross Profit TTM
2.2B
EBITDA
1.6B
Diluted Eps TTM
7.41
Quarterly Earnings Growth YOY
0.82
EPS Estimate Current Year
14.93
EPS Estimate Next Year
17.07
EPS Estimate Current Quarter
3.45
EPS Estimate Next Quarter
3.47

Analyst Recommendation

Buy
    81%Buy
    13%Hold
    4%Sell
Based on 22 Wall street analysts offering stock ratings for Icon Public Limited Company(by analysts ranked 0 to 5 stars)
Based on 22 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
18
18
17
Hold
3
3
4
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 21.89%

Current $288.23
Target $351.31

Company Financials

FY18Y/Y Change
Revenue
2.6B
↑ 47.62%
Net Income
322.8M
↑ 18.27%
Net Profit Margin
12.44%
↓ 3.08%
FY19Y/Y Change
Revenue
2.8B
↑ 8.09%
Net Income
374.0M
↑ 15.85%
Net Profit Margin
13.33%
↑ 0.89%
FY20Y/Y Change
Revenue
2.8B
↓ 0.3%
Net Income
327.8M
↓ 12.35%
Net Profit Margin
11.72%
↓ 1.61%
FY21Y/Y Change
Revenue
5.5B
↑ 95.93%
Net Income
153.2M
↓ 53.27%
Net Profit Margin
2.79%
↓ 8.93%
FY22Y/Y Change
Revenue
7.7B
↑ 41.24%
Net Income
505.3M
↑ 229.87%
Net Profit Margin
6.53%
↑ 3.74%
FY23Y/Y Change
Revenue
8.1B
↑ 4.89%
Net Income
612.3M
↑ 21.18%
Net Profit Margin
7.54%
↑ 1.01%
Q3 FY22Q/Q Change
Revenue
1.9B
↑ 0.37%
Net Income
160.2M
↑ 38.38%
Net Profit Margin
8.25%
↑ 2.27%
Q4 FY22Q/Q Change
Revenue
2.0B
↑ 1.01%
Net Income
117.4M
↓ 26.67%
Net Profit Margin
5.99%
↓ 2.26%
Q1 FY23Q/Q Change
Revenue
2.0B
↑ 0.84%
Net Income
116.7M
↓ 0.67%
Net Profit Margin
5.9%
↓ 0.09%
Q2 FY23Q/Q Change
Revenue
2.0B
↑ 2.11%
Net Income
115.6M
↓ 0.91%
Net Profit Margin
5.72%
↓ 0.18%
Q3 FY23Q/Q Change
Revenue
2.1B
↑ 1.72%
Net Income
163.7M
↑ 41.58%
Net Profit Margin
7.96%
↑ 2.24%
Q4 FY23Q/Q Change
Revenue
2.1B
↑ 0.54%
Net Income
216.4M
↑ 32.23%
Net Profit Margin
10.47%
↑ 2.51%
FY18Y/Y Change
Total Assets
2.4B
↑ 9.17%
Total Liabilities
1000.0M
↑ 4.64%
FY19Y/Y Change
Total Assets
2.9B
↑ 21.84%
Total Liabilities
1.3B
↑ 28.95%
FY20Y/Y Change
Total Assets
3.5B
↑ 19.2%
Total Liabilities
1.6B
↑ 22.93%
FY21Y/Y Change
Total Assets
17.4B
↑ 401.68%
Total Liabilities
9.3B
↑ 487.98%
FY22Y/Y Change
Total Assets
17.2B
↓ 1.16%
Total Liabilities
8.7B
↓ 6.79%
FY23Y/Y Change
Total Assets
17.0B
↓ 1.14%
Total Liabilities
7.7B
↓ 10.8%
Q3 FY22Q/Q Change
Total Assets
17.1B
↑ 0.53%
Total Liabilities
8.9B
↓ 0.04%
Q4 FY22Q/Q Change
Total Assets
17.2B
↑ 0.35%
Total Liabilities
8.7B
↓ 2.25%
Q1 FY23Q/Q Change
Total Assets
17.3B
↑ 0.59%
Total Liabilities
8.6B
↓ 0.63%
Q2 FY23Q/Q Change
Total Assets
17.1B
↓ 1.03%
Total Liabilities
8.3B
↓ 3.72%
Q3 FY23Q/Q Change
Total Assets
17.0B
↓ 0.45%
Total Liabilities
8.1B
↓ 2.87%
Q4 FY23Q/Q Change
Total Assets
17.0B
↓ 0.24%
Total Liabilities
7.7B
↓ 4.01%
FY18Y/Y Change
Operating Cash Flow
264.0M
↑ 441.67%
Investing Cash Flow
-37.3M
↓ 79.03%
Financing Cash Flow
-108.4M
↓ 9.12%
FY19Y/Y Change
Operating Cash Flow
412.5M
↑ 56.26%
Investing Cash Flow
-162.0M
↑ 334.44%
Financing Cash Flow
-125.4M
↑ 15.69%
FY20Y/Y Change
Operating Cash Flow
594.7M
↑ 44.16%
Investing Cash Flow
-46.6M
↓ 71.25%
Financing Cash Flow
-235.0M
↑ 87.41%
FY21Y/Y Change
Operating Cash Flow
829.1M
↑ 39.42%
Investing Cash Flow
-6.0B
↑ 12834.2%
Financing Cash Flow
5.1B
↓ 2276.28%
FY22Y/Y Change
Operating Cash Flow
563.3M
↓ 32.06%
Investing Cash Flow
-145.9M
↓ 97.58%
Financing Cash Flow
-864.2M
↓ 116.9%
Q3 FY22Q/Q Change
Operating Cash Flow
213.8M
↑ 17.43%
Investing Cash Flow
-38.3M
↑ 31.76%
Financing Cash Flow
-186.2M
↑ 101.59%
Q4 FY22Q/Q Change
Operating Cash Flow
-59.4M
↓ 127.8%
Investing Cash Flow
-58.9M
↑ 53.55%
Financing Cash Flow
-193.1M
↑ 3.74%
Q1 FY23Q/Q Change
Operating Cash Flow
175.5M
↓ 395.33%
Investing Cash Flow
-28.0M
↓ 52.38%
Financing Cash Flow
-157.1M
↓ 18.68%
Q2 FY23Q/Q Change
Operating Cash Flow
203.9M
↑ 16.17%
Investing Cash Flow
-35.5M
↑ 26.59%
Financing Cash Flow
-172.8M
↑ 10.0%
Q3 FY23Q/Q Change
Operating Cash Flow
341.5M
↑ 67.51%
Investing Cash Flow
-35.5M
↑ 0.0%
Financing Cash Flow
-258.7M
↑ 49.72%

Technicals Summary

Sell

Neutral

Buy

Icon Public Limited Company is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Icon Public Limited Company
Icon Public Limited Company
-14.15%
27.13%
39.77%
39.67%
121.73%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-10.04%
11.56%
-2.91%
-10.51%
114.97%
Agilent Technologies Inc.
Agilent Technologies Inc.
-9.88%
21.51%
-2.07%
0.2%
75.64%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-6.08%
17.32%
-3.74%
12.94%
110.27%
Danaher Corp.
Danaher Corp.
-6.42%
14.42%
-5.17%
-2.62%
85.63%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-9.75%
23.72%
14.85%
5.05%
69.75%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Icon Public Limited Company
Icon Public Limited Company
39.38
39.38
1.17
14.93
0.07
0.04
NA
112.02
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
47.4
47.4
4.75
11.13
0.81
0.23
NA
17.88
Agilent Technologies Inc.
Agilent Technologies Inc.
31.68
31.68
2.7
5.5
0.21
0.08
0.01
21.12
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
35.1
35.1
2.81
21.55
0.13
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
41.83
41.83
3.13
7.62
0.08
0.04
0.0
72.36
Iqvia Holdings Inc.
Iqvia Holdings Inc.
31.29
31.29
1.33
11.11
0.23
0.05
NA
33.67
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Icon Public Limited Company
Icon Public Limited Company
Buy
$24.1B
121.73%
39.38
7.54%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$39.7B
114.97%
47.4
23.08%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$38.8B
75.64%
31.68
18.35%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$206.7B
110.27%
35.1
13.99%
Danaher Corp.
Danaher Corp.
Buy
$175.0B
85.63%
41.83
19.94%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$41.5B
69.75%
31.29
9.06%

Institutional Holdings

  • WCM Investment Management

    8.33%

  • Massachusetts Financial Services Company

    6.71%

  • Wellington Management Company LLP

    4.15%

  • FMR Inc

    3.67%

  • Lazard Asset Management LLC

    3.35%

  • Boston Partners Global Investors, Inc

    3.24%

Company Information

icon is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. we specialise in the strategic development, management and analysis of programmes that support clinical development - from compound selection to phase i-iv clinical studies. in a highly fragmented industry, we are one of a small group of organisations with the capability and expertise to conduct clinical trials and development projects on either a local or global basis. we have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution. we are also an 'end-to-end'​ pharmacovigilance service provider and this includes post marketing surveillance activities too.

Organization
Icon Public Limited Company
Employees
41100
CEO
Dr. John Climax Ph.D.
Industry
Health Technology

Discover More

FAQs